AR7 NEW
| Price | $31 | $63 | $97 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: AR7 | CAS No.: 80306-38-3 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | AR7 |
| Description | AR7 is a retinoic acid receptor α (RARα) antagonist. |
| In vitro | Chaperone-mediated autophagy (CMA) contributes to cellular quality control and the cellular response to stress through the selective degradation of cytosolic proteins in lysosomes. Decrease in CMA activity occurs in aging and in age-related disorders. Signaling through the retinoic acid receptor alpha (RARα) inhibits CMA. AR7, an RARα antagonist, significantly activates CMA activity in mouse fibroblasts. A marked increase in CMA-activating potency is found when AR7 and GR1 are combined, supporting their cooperative effect. Treatment with the transcriptional repressor Actinomycin D partially reduces the stimulatory effect of AR7 on CMA, consistent with transcriptional changes contributing to the upregulation of CMA. The antagonistic effect of the retinoid derivatives likely results from a combination of tight binding to RARα and high stability. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1.25 mg/mL (4.85 mM), Suspension. DMSO : 12.5 mg/mL (48.5 mM), Sonication is recommended. 10% DMSO+90% Saline : < 1.25 mg/mL (4.85 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| Keywords | RetinoidReceptor | Retinoid X receptors | Retinoid Receptor | Retinoic acid receptors | retinoic | receptor | RARα | RAR/RXR | macroautophagy | Inhibitor | inhibit | CMA | AR-7 | AR7 | AR 7 | acid |
| Inhibitors Related | Isotretinoin | 1,3,5-Triisopropylbenzene | Adapalene | Oxybenzone | MSU-42011 | Retinoic acid | 2,4-Di-tert-butylphenol | Fenretinide | Tamibarotene | Bexarotene | TTNPB | Magnolol |
| Related Compound Libraries | Nuclear Receptor Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Inhibitor Library | NO PAINS Compound Library | PPI Inhibitor Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Transcription Factor-Targeted Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY